AstraZeneca Playing Leapfrog In Immunotherapy: How It Plans To Lead From Behind

AstraZeneca has not been at the front of the PD-1/L1 immune checkpoint inhibitor race, but execs explain how the company is making strategic choices in immuno-oncology to make it first to the finish line in unique areas.